Guardian Pharmacy Services, Inc.

NYSE:GRDN

Medical - Distribution

Healthcare
$48.84 +0.39%

+$0.17 today

Market cap
$3.09B
Beta
0.08
P/E (TTM)
52.0
EPS (TTM)
$0.84
52W Low $19.30High $44.00

Volume 0.45M

Average 0.48M

GRDN Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Guardian Pharmacy Services, Inc.NYSE: GRDN

Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026

Depreciation & amortization grows, but more slowly than its trailing trend

Q2 FY2026 depreciation & amortization of $5.81M rose 5.8% year over year, behind the +11.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 2.8% from the prior quarter. Over 3 fiscal years it compounded at +10.5% a year.

Context

  • Depreciation & amortization amounted to 1.5% of revenue in FY2025, unchanged from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +5.8% toward the trailing-twelve-month pace of +11.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$5.81M-2.8% QoQ
Last fiscal yearDec 2025
$22.34M+13.0% YoY
LTMJun 2026
$23.36M+11.8% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+5.8%——
1 year+13.0%——
3-year CAGR+10.5%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
22.34M USD
Year-over-year change
+13.0%
4-year CAGR
+7.8%

Depreciation & Amortization vs competitors

How GRDN compares with its peers on the latest reported figures

  • GRDN's LTM Jun 2026 depreciation & amortization of $23.36M is the 6th largest of the 11 companies compared; the peer median is $15.21M.
  • Its year-over-year change of +11.8% is the 3rd highest of 11, against a peer median of +2.2%.
  • Depreciation & amortization amounts to 1.6% of revenue for GRDN, versus a peer median of 3.1%.
GRDN Competitors Peer median
Depreciation & Amortization for GRDN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
QDELQuidelOrtho CorporationLTM Mar 2026$447.8M +0.5%+15.9%16.9%
NHCNational HealthCare CorporationLTM Sep 2026$49.13M +10.2%+3.5%3.1%
TXG10x Genomics, Inc.LTM Jun 2026$45.93M +12.6%+9.9%7.4%
TWSTTwist Bioscience CorporationLTM Sep 2026$26.48M +6.6%-3.3%5.8%
MDPediatrix Medical Group, Inc.LTM Sep 2026$23.78M +3.1%-15.1%1.2%
GRDNGuardian Pharmacy Services, Inc.LTM Jun 2026$23.36M +11.8%+10.5%1.6%
PRCTPROCEPT BioRobotics CorporationLTM Mar 2026$6.65M +20.4%+31.0%2.1%
EWTXEdgewise Therapeutics, Inc.LTM Sep 2026$2.35M +1.4%+61.5%—
MESOMesoblast LimitedLTM Jun 2026$2.14M -66.6%—1.8%
JANXJanux Therapeutics, Inc.LTM Mar 2026$1.98M -3.3%+34.1%9.2%
NUVBNuvation Bio Inc.LTM Jun 2026$666K -163.6%+106.0%0.4%
Peer median (excluding GRDN) $15.21M+2.2%+15.9%3.1%

Competitors are the stored peer set for GRDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income28.33M49.66M37.72M(71.03M)49.22M
Depreciation & Amortization16.53M16.56M18.23M19.77M22.34M
Deferred Income Tax00003.07M
Stock-Based Compensation13.03M(3.38M)(6.09M)131.49M13.85M
Change in Working Capital(1.47M)(18.72M)15.6M(29.41M)6.38M
Accounts Receivables(7.71M)(16.79M)(14.3M)(25.49M)(8.55M)
Inventory(240K)(8.12M)4.43M(1.15M)(877K)
Accounts Payables9.78M13.37M6.3M13.23M16.4M
Other Working Capital(3.3M)(7.17M)19.18M(16M)(586K)
Other Non-Cash Items2.08M4.4M5.35M7.14M5.43M
Operating Cash Flow58.5M48.52M70.82M57.96M100.29M
Capital Expenditures(9.28M)(16.77M)(14.56M)(16.37M)(19.58M)
Acquisitions (Net)(4.4M)(2M)(985K)(14.71M)0
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities535K874K2.1M671K(12.68M)
Investing Cash Flow(13.15M)(17.9M)(13.44M)(30.41M)(32.26M)
Debt Repayment(6.1M)(2.8M)(2.89M)(36.48M)(4.98M)
Common Stock Issued000119.78M27.45M
Common Stock Repurchased000(55.18M)(29.04M)
Dividends Paid(17.36M)(30.8M)(38.42M)(35.75M)0
Other Financing Activities(13.34M)(11.42M)(15.92M)(16.02M)(497K)
Financing Cash Flow(36.79M)(45.03M)(57.23M)(23.65M)(7.07M)
Effect of Forex Changes00000
Net Change in Cash8.56M(14.41M)145K3.91M60.96M
Free Cash Flow49.22M31.75M56.26M41.59M80.71M

Guardian Pharmacy Services, Inc.

NYSE:GRDN

Intrinsic Alpha fair value

Locked

Current Price

$48.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.